Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer. The company operates within the biotechnology and immuno-oncology industries, with a strategic emphasis on identifying novel cancer targets that are recognized by T cells but are largely invisible to conventional antibody-based approaches. Its core value proposition centers on a proprietary platform designed to discover disease-specific TCR targets with high precision.
The company’s primary business activity is the research and development of autologous TCR-T cell therapies, with lead programs targeting hematologic malignancies and solid tumors. TScan does not generate commercial revenue and remains dependent on research funding, equity financing, and strategic collaborations. Founded in 2018, the company emerged from academic research and platform development aimed at systematically mapping T cell antigen recognition, and it subsequently transitioned to a publicly traded entity to support clinical development and pipeline expansion.
Business Operations
TScan operates as a single-reportable segment focused on immuno-oncology research and development. Its core operations include target discovery using its proprietary TScan platform, preclinical validation, clinical development, and early-stage manufacturing of engineered T cell therapies. The company’s pipeline includes multiple clinical and preclinical candidates designed to target antigens associated with hematologic cancers such as acute myeloid leukemia, as well as select solid tumors.
Operational activities are primarily based in the United States, with research, development, and corporate functions integrated under one organizational structure. The company controls key intellectual property related to its antigen discovery technology and TCR engineering capabilities. TScan has entered into selective research collaborations and manufacturing-related partnerships; however, publicly available sources do not indicate any material joint ventures or revenue-generating subsidiaries as of the most recent filings. Data inconclusive based on available public sources regarding long-term manufacturing outsourcing arrangements.
Strategic Position & Investments
TScan’s strategy is centered on building a differentiated pipeline of TCR-T therapies by leveraging its discovery platform to identify targets with high tumor specificity and reduced off-target risk. Growth initiatives are focused on advancing lead clinical programs through early- and mid-stage trials while expanding the target discovery engine to support a broader portfolio of oncology indications. The company prioritizes internally developed assets rather than late-stage acquisitions.
Investment activity has primarily consisted of internal research and development spending rather than external portfolio investments. No material acquisitions have been disclosed in public filings, and the company does not report ownership of notable subsidiary operating companies. Emerging areas of focus include expanding the applicability of TCR-T therapies beyond hematologic malignancies and refining antigen discovery methodologies to improve clinical scalability and safety.
Geographic Footprint
TScan’s operations are primarily concentrated in North America, with its headquarters and principal facilities located in the United States. Research and clinical development activities are largely U.S.-based, supported by domestic clinical trial sites and academic collaborators. The company’s geographic footprint reflects its clinical-stage status, with limited direct international infrastructure.
Despite a primarily domestic operational base, TScan’s clinical programs and intellectual property strategy are designed for global relevance. The company participates in international scientific and medical communities through publications and conferences, and its therapies are intended to address global oncology markets. Data inconclusive based on available public sources regarding material long-term operational facilities outside the United States.
Leadership & Governance
TScan was founded by Gavin MacBeath, who continues to play a central role in shaping the company’s scientific and strategic direction. The leadership team combines expertise in immunology, drug development, and biotechnology operations, with governance oversight provided by a board that includes industry and investment professionals. The company’s leadership philosophy emphasizes rigorous target validation, data-driven clinical development, and disciplined capital allocation.
Key executives include:
- Gavin MacBeath – Founder and Chief Executive Officer
- David Southwell – Chief Financial Officer
- Steve Armstrong – Chief Medical Officer
- Alison Moore – Chief Operating Officer
- David Palmer – Chief Scientific Officer
The leadership team’s strategic vision focuses on establishing TScan as a leader in TCR-based immunotherapies by advancing clinically differentiated assets while maintaining platform innovation and operational efficiency.